However, none of the pediatric T-ALL PDX samples respond to single-agent ruxolitinib in the absence of IL7, whereas MEK inhibitors enhance steroid responsiveness in both IL7-dependent and IL7-independent steroid-resistant pediatric T-ALL samples, highlighting the central role for MAPK-ERK signaling in steroid resistance [76]. This evidence concerns the gene MAP2K7 and acute lymphoblastic leukemia.